

ASX Announcement

16 October 2025

First OncoSil™ treatment in Germany

Sydney, Australia – 16 October 2025: Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) ("OncoSil" or "the Company") is pleased to announce the first patient treatment in Germany using the OncoSil™ device.

The successful treatment was performed on 15 October 2025 at Universitätsklinikum Augsburg, a leading university hospital renowned for its excellence in oncology. This important milestone marks the commencement of OncoSil's commercial activities in Germany, the largest and most influential healthcare market in Europe.

Germany represents a key strategic market for OncoSil Medical, given its advanced healthcare infrastructure, strong clinical expertise in oncology, and early adoption of innovative medical technologies. The Company will continue to collaborate closely with German physicians, healthcare institutions and health insurers to facilitate broader patient access to the OncoSil™ device.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"We are very proud to announce the first OncoSil™ treatment in Germany, a major milestone for the Company. This represents our initial commercial entry into the German market, which is one of Europe's most important and sophisticated medical device markets.

From a broader European perspective, this initial OncoSil™ treatment in Germany is further evidence that our targeted penetration of key countries across the Continent is being delivered.

We now look forward to working with leading German physicians to bring our innovative treatment to more pancreatic cancer patients over the months and years ahead."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director

E: <u>nigel.lange@oncosil.com</u> T: +49 30 300 149 3043 Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries

E: tim.luscombe@bio101.com david.wood@bio101.com

T: +61 429 707 079 & +61 408 393 670

Ms. Julia Maguire The Capital Network

Media and Investor Enquiries
E: julia@thecapitalnetwork.com.au

1

T: +61 2 7257 7338



About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil[™] has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil[™] is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en

About University Hospital Augsburg (Universitätsklinikum Augsburg)

University Hospital Augsburg is with about 1,750 beds one of the largest medical centers in Germany located in Augsburg. It is a teaching hospital of the Universität Augsburg and the only hospital of maximal care in Swabia (Bavaria). The hospital has two locations in Augsburg. The location in the Stenglinstraße (Kriegshaber) and the location in the Sauerbruchstraße (Haunstetten). The University Hospital Augsburg comprises a total of 23 clinics and three institutes, as well as other medical treatment areas and centers. More than 6,000 employees, including around 900 doctors and around 2,500 nurses, work for the health of patients.